NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Transposon Therapeutics

Transposon Therapeutics

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://transposonrx.com/

Last Round

Grant

Mar 4, 2026

Total Funding Raised

$54.12M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Transposon Therapeutics is a biotechnology company developing a platform of novel nucleoside reverse transcriptase inhibitors for the treatment of neurodegenerative and aging-related diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologysmall molecule drugsneurodegenerative diseaseLINE-1 inhibitorclinical-stage biotechdrug developmentneuroinflammationprogressive supranuclear palsyPSPAlzheimer's treatmentfast track designationdisease-modifying therapybiotech startupclinical trialsdrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Transposon Therapeutics Comparables

Compare Transposon Therapeutics with similar companies based on industry and business-model similarity.

Transposon Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Asceneuron
78%
Vesper Bio ApS
71%
Coya Therapeutics, Inc.
70%

Transposon Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 4, 2026
GrantJul 9, 2025
DebtJul 15, 2024
VC RoundJan 12, 2023
Series ADec 9, 2020
Seed
May 6, 2020

Key People

Founding team and executive leadership

Eckard Weber

Founder And Chief Innovation Officer

Founding Team

Lynne Rollins

CFO

Executive Team

Transposon Therapeutics Investors

Notable investors and investment history

Transposon Therapeutics investors
InvestorRounds
Domain AssociatesSeed, Series A, VC Round
Canaan PartnersSeed, Series A, VC Round
Catalys PacificSeries A
ARPA-HGrant
Lumira VenturesSeries A
Alzheimer's Drug Discovery FoundationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 4, 2026

    $22M grant round closed.

Transposon Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Transposon Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Transposon Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range12
Year Founded2019
Last FundingMar 4, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.